Optimizing the Management of Acute Myeloid Leukemia: Individualized Therapy

Target Audience

This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.

Program Overview

Recently approved agents have expanded the horizon of treatment for acute myeloid leukemia (AML). Most of these newer drugs target specific genetic mutations, AML subsets, or patient populations, which amplifies the importance of determining cytogenetic and molecular profiles and stratifying risk in order to develop individual treatment plans. This activity addresses advances in the treatment of AML, appropriate use of novel therapies, management of therapy-related toxicities, and provides an overview of investigational therapies and maintenance therapy.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Describe diagnostic testing for risk stratification in AML and the role of cytogenetic and molecular factors in treatment selection
Identify individualized AML treatment approaches based on efficacy and safety data, as well as patient- and disease-related characteristics
Implement strategies to recognize, monitor, and manage toxicities associated with new agents used in the treatment of AML